Response to Letter Regarding Article, “Endovascular Stroke Therapy: Tirofiban Is Associated With Risk of Fatal Intracerebral Hemorrhage and Poor Outcome”

We would like to thank Schlachetzki et al for their comments and interest in our article about the administration of tirofiban, which may cause a higher incidence of fatal intracerebral hemorrhage and poor outcome in patients who have received endovascular stroke therapy.1,2We fully agree with the highlighted limitations, which were already mentioned in our article (eg, higher rate of stenting in the tirofiban group). Of course, the main limitation is the nonrandomized study design, which gives imbalances between the groups. A further limitation of our study is that tirofiban was not only administered after stent implantation, but also in patients in whom endothelial damage was suspected (for example, …